All material subject to strictly enforced copyright laws. © 2022 Euromoney Institutional Investor PLC group
EquityEquity IPOs

First longevity firm to list in Europe bets on 'major exit'

Eric Leire 1.jpg

It could take years to develop a gene therapy to slow aging, but much less for big pharma to scoop up Genflow Biosciences

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login